UDG Healthcare

UDG Healthcare

UDG Healthcare Socially Speaking

UDG Healthcare News, Fundamentals and Discussion on:

Interactive Investor | Financial Times | ADVFN | Motley Fool | Proactive Investors | Bloomberg Markets
Ayondo
Ayondo

UDG Healthcare on Social Media


UDG Healthcare RNS, News & Media


Headline
3 Aug 2017
RNS press release - Third Quarter Trading Update from Proactive Investors
2 Aug 2017
RNS press release - Holding(s) in Company from Proactive Investors
31 Jul 2017
RNS press release - Holding(s) in Company from Proactive Investors
25 Jul 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
17 Jul 2017
RNS press release - Acquisition of US healthcare communications firm from Proactive Investors
13 Jul 2017
RNS press release - Notice of Q3 2017 Trading Update from Proactive Investors
12 Jul 2017
RNS press release - Holding(s) in Company from Proactive Investors
12 Jul 2017
RNS press release - Acquisition of US healthcare consultancy firm from Proactive Investors
11 Jul 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
11 Jul 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
6 Jul 2017
RNS press release - Holding(s) in Company from Proactive Investors
6 Jul 2017
RNS press release - Holding(s) in Company from Proactive Investors
4 Jul 2017
RNS press release - Block listing Interim Review from Proactive Investors
29 Jun 2017
RNS press release - Directorate Change from Proactive Investors
21 Jun 2017
RNS press release - Holding(s) in Company from Proactive Investors
15 Jun 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
15 Jun 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
15 Jun 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
6 Jun 2017
RNS press release - Holding(s) in Company from Proactive Investors
6 Jun 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
1 Jun 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
31 May 2017
RNS press release - Total Voting Rights from Proactive Investors
31 May 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
24 May 2017
RNS press release - Holding(s) in Company from Proactive Investors
23 May 2017
RNS press release - Half-year Report from Proactive Investors
17 May 2017
RNS press release - Holding(s) in Company from Proactive Investors
11 May 2017
RNS press release - Holding(s) in Company from Proactive Investors
10 May 2017
RNS press release - Holding(s) in Company from Proactive Investors
3 May 2017
RNS press release - Holding(s) in Company from Proactive Investors
3 May 2017
RNS press release - Notice of Interim Results from Proactive Investors
12 Apr 2017
RNS press release - Appointment announcement from Proactive Investors
3 Apr 2017
RNS press release - Sharp announces capacity expansion in US and UK from Proactive Investors
3 Apr 2017
RNS press release - Director Declaration from Proactive Investors
31 Mar 2017
RNS press release - Total Voting Rights from Proactive Investors
29 Mar 2017
RNS press release - Holding(s) in Company from Proactive Investors
28 Mar 2017
RNS press release - Director/PDMR Shareholding from Proactive Investors
21 Mar 2017
RNS press release - Holding(s) in Company from Proactive Investors
6 Mar 2017
RNS press release - Holding(s) in Company from Proactive Investors
27 Feb 2017
RNS press release - Holding(s) in Company from Proactive Investors
16 Feb 2017
RNS press release - Director Declaration from Proactive Investors
7 Feb 2017
RNS press release - Result of AGM from Proactive Investors
7 Feb 2017
RNS press release - Board Appointment from Proactive Investors
7 Feb 2017
RNS press release - 1st Quarter Trading Update from Proactive Investors
6 Feb 2017
RNS press release - Total Voting Rights from Proactive Investors
16 Dec 2016
RNS press release - Annual Report & AGM Documents from Proactive Investors
13 Dec 2016
RNS press release - Holding(s) in Company from Proactive Investors
9 Dec 2016
RNS press release - Director/PDMR Shareholding from Proactive Investors
8 Dec 2016
RNS press release - Holding(s) in Company from Proactive Investors
5 Dec 2016
RNS press release - Holding(s) in Company from Proactive Investors

UDG Healthcare 3 Month Chart


Enjoyed your visit? Earn a little social karma:

Share on Twitter Share on Facebook


Click for UDG Healthcare Discussion on ADVFN

UDG Healthcare Discussion on ADVFN

UDG Healthcare Discussion on Interactive Investor

Re: Results by Our Haven

  Thu, 25 May 2017 20:01:00 GMT

Did when they issued but normal service now restored

By Our Haven



Re: Results by Yertiz

  Thu, 25 May 2017 17:25:00 GMT

Well that didn't work, did it? 😎

By Yertiz



Re: Results by Our Haven

  Thu, 25 May 2017 11:10:00 GMT

Of course the next broker Jeffries downgraded the stock to hold to depress the gains.

By Our Haven



Results by Our Haven

  Tue, 23 May 2017 09:03:00 GMT

Some excellent numbers here. All time high today with potential for more upside? Broker certainly thinks so.

By Our Haven



Re: TGISVP - UDG Healthcare by Our Haven

  Tue, 03 Jan 2017 12:25:00 GMT

I see your logic Wexboy but this is pretty much the same logic you employed back in 2014, excluding currency movements and who is to say what the Trump effect will bring on that score. Best of luck for 2017.

By Our Haven



TGISVP - UDG Healthcare by Wexboy

  Tue, 03 Jan 2017 04:24:00 GMT

2016 – The Great Irish Share Valuation Project (Part IV):

Company: UDG Healthcare (UDG:LN)

Last TGISVP Post: Here

Market Cap: GBP 1,653 M

Price: GBP 668p

Ugh, well that looks like a disastrous call!? ‘Course, there’s plenty of water under the bridge since (& fair value estimates obviously change), but I anticipated a substantial UDG price decline back in 2014…in reality, the shares almost doubled in the last few years! So, time to stick or twist? Trouble is, UDG Healthcare’s one of those suspect Irish stocks (which shall remain nameless here) which consistently report a significant gap between IFRS & adjusted earnings, and (perhaps more importantly) between adjusted operating profit & underlying Op FCF…so which figures exactly should one focus on when attempting a valuation?! Not to mention UDG’s colossal P/E multiple – 27.7 times continuing adjusted diluted EPS, no less – which doesn’t remotely reflect the pedestrian underlying earnings growth we’ve actually seen in recent years. But let’s back up here…

And go back to 2015, which marked a decisive turning-point for UDG Healthcare – in Q3, the company announced the €0.4 billion sale of its supply chain services division, the original core business of United Drug (inc. its Irish pharmaceutical wholesaling business). [The CEO Liam Fitzgerald marked the occasion by also pre-announcing his own early retirement, after leading the company for 15 years, to be replaced by COO Brendan McAtamney]. Thereby unveiling a higher margin & (supposedly) faster growth company, focusing on: i) sales, marketing & healthcare communications services, and ii) pharmaceutical contract packaging & clinical trials materials – all intended to exploit the ongoing trend for healthcare companies to outsource non-core & specialist activities on an international basis.

Which has delivered a (totally transformed) 11.1% adjusted operating margin on continuing ops. revenue of €934 million – unfortunately, we continue to see the same cash flow issue each year, on average a 20%+ shortfall in Op FCF (vs. adjusted operating profit) over 2015-16, implying an adjusted 8.6% margin is more appropriate in determining a suitable 0.875 Price/Sales multiple. [There will be a meaningful currency hit next year from a stronger dollar (UDG will report in dollars from now on), but I expect this to be broadly offset by underlying revenue growth & recent acquisitions]. Interest coverage remains within a reasonable range, based on €275 million of debt left outstanding…but we can treat the effective sale proceeds, i.e. €384 million of surplus cash, as incremental value. As for earnings, UDG’s two main divisions boast underlying 25%+ operating profit growth over the 2010-2015 period, but in reality their 2016 growth rate isn’t much better than the sub-9% growth in underlying adjusted diluted EPS over the last 3 years – bearing in mind UDG may still be in transition, plus the usual stability of its earnings, we’ll basically split the difference in growth trajectories & assign what seems like a pretty balanced 15.0 Price/Earnings multiple:

(EUR 0.2861 Adj Dil EPS * 15.0 P/E + (943 M Rev * 0.875 P/S + 384 M Cash) / 247 M Shares) / 2 * 0.8438 EUR/GBP = GBP 387p

The numbers have changed, but I still reach the same conclusion – UDG’s as wildly over-valued as ever. It might be foolish setting this price target, because the outcome’s probably binary… Once they’re comfortable with an investment thesis, plus a valuation multiple/range, investors are loathe to change their minds…so if necessary, companies often have the time/space to grow into any valuation eventually. Of course, if things start going horribly wrong, everybody & their mother suddenly wakes up & notices all kinds of issues – the earnings gap, mediocre earnings growth (vs. the P/E), poor cash flow, a looming debt burden, etc. Of course, the latter doesn’t apply here (for once), as UDG’s in a comfortable net cash position (though doubtless it’s


By Wexboy



Going strong by wineberry

  Mon, 21 Dec 2015 17:06:00 GMT

UDG is one of Momentum Investor's major recommendations for this month with the opportunity for serious growth in its Ashfield Division. Its poorest performing sector -the old wholesale distribution business - is being sold off for E407.5m subject to regulatory approval - completion anticipated next June. This will put the company into a net cash position with a E500m borrowing facility and well able to make further acquisitions.

Right sector, right time but DYOR as always.


By wineberry



UDG Broker Views............. by oldjoe1

  Tue, 24 Mar 2015 14:22:00 GMT

<b>Analysts Set Udg Healthcare PLC PT at $408.00 (LON:UDG)
March 21st, 2015 Updated Tues 25 March/2015 - Filed Under - by Samantha Reynolds</b>

Shares of Udg Healthcare PLC (LON:UDG) have earned a consensus recommendation of “Buy” from the seven brokerages that are covering the company, American Banking & Market News reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is GBX 408 ($6.02).

Udg Healthcare PLC (LON:UDG) opened at 465.70 on Wednesday. Udg Healthcare PLC has a 52-week low of GBX 315.20 and a 52-week high of GBX 479.03. The stock’s 50-day moving average is GBX 445. and its 200-day moving average is GBX 378.. The company’s market cap is £1.13 billion.

UDG has been the subject of a number of recent research reports. Analysts at N+1 Singer reiterated a “hold” rating on shares of Udg Healthcare PLC in a research note on Friday, March 6th. Analysts at Berenberg Bank raised their price target on shares of Udg Healthcare PLC from GBX 425 ($6.27) to GBX 455 ($6.71) and gave the company a “hold” rating in a research note on Thursday, February 12th. Analysts at Jefferies Group LLC reiterated a “buy” rating and set a GBX 400 ($5.90) price target on shares of Udg Healthcare PLC in a research note on Tuesday, February 3rd. Finally, analysts at Investec raised their price target on shares of Udg Healthcare PLC from GBX 340 ($5.02) to GBX 387 ($5.71) and gave the company a “hold” rating in a research note on Tuesday, February 3rd.

UDG Healthcare plc is an international provider of services to healthcare manufacturers and pharmaceutical retailers. It is engaged in supply chain, packaging, medical, regulatory, and sales and marketing services. The Company provides outsourced services. Aquilant is a provider of healthcare and scientific products and services, providing outsource sales, marketing, distribution and engineering for the medical and scientific sectors.


By oldjoe1



Re: UDG ..New All Time High.... by oldjoe1

  Tue, 03 Feb 2015 12:07:00 GMT

UPDATE 2 – UDG Healthcare expects 5 – 8 pct rise in full – year EPS

03 Feb 2015 - 11:11

Says reported EPS to be higher if current exchange rates persist
To take 10 mln euro restructuring charge this year
Sees 2 pct benefit to EPS from restructuring
Shares rise 5 pct to record high
(Adds details, analyst and CFO comments; updates share movement)

By Roshni Menon

Feb 3 (Reuters) – UDG Healthcare Plc said it expected a 5-8 percent rise in adjusted full-year earnings per share on a constant-currency basis, and that reported EPS could be higher than this if exchange rates remained around current levels.

Shares in the FTSE-250 company, which provides outsourced sales and marketing, drug distribution and packaging services to healthcare companies, rose more than 5 percent to a record high of 417.5 pence in morning trade on Tuesday.

Dublin-based UDG, formerly known as United Drug, reports results in euros but makes about 70 percent of its profit in pounds and dollars. ...

The euro has fallen about 10 percent against the dollar and about 3 percent against the pound since the start of the company's 2015 financial year on Oct. 1.

"UDG has left enough room for upgrades through FY15 if positive momentum continues," Jefferies analysts said in a note.

The company reported adjusted earnings of 28.77 euro cents per share in the year ended Sept. 30. Average exchange rates were 82 pence and $1.36 to the euro, UDG said. ...

"At current exchange rates, we would expect a further 5-6 percent benefit on the bottom line, meaning guidance implies adjusted EPS growth of 10-13 percent for the full year," Berenberg analysts said in a note.

Chief Financial Officer Alan Ralph told Reuters the company would take a charge of about 10 million euros this year, related mainly to the restructuring of its healthcare communications business and for changes in its United Drug supply chain unit.

The restructuring is expected boost earnings per share by 2 percent in the current financial year and by an additional 1 to 2 percent the following year, Ralph added.

UDG shares were up 4.1 percent at 413 pence at 1035 GMT.

Shares of the company, which has a market value of about 970 million pounds ($1.46 billion), have gained more than 20 percent since the company reported full-year results in November. ($1 = 0.6641 pounds)

(Reporting by Roshni Menon in Bengaluru; Editing by Gopakumar Warrier and Ted Kerr) ((roshni.menon@thomsonreuters.com; within UK +44 20 7542 1810, outside UK +91 80 6749 1136; Reuters Messaging: roshni.menon.thomsonreuters.com@reuters.net;)

Keywords: UDG HEALTH OUTLOOK/


By oldjoe1



UDG ..New All Time High.... by oldjoe1

  Tue, 03 Feb 2015 10:26:00 GMT

UDG UDG Healthcare, gaps up to a new all time high on excellent update this morning. Presently + 5.10% on the day.

LINK


By oldjoe1



Re: UDG Well Ahead Of Last Year............ by oldjoe1

  Tue, 03 Feb 2015 08:02:00 GMT

03 Feb 2015 UDG Healthcare PLC UDG N+1 Singer Buy 414.15 396.70 - - Reiterates

By oldjoe1



Re: UDG Well Ahead Of Last Year............ by oldjoe1

  Tue, 03 Feb 2015 07:54:00 GMT

UDG Healthcare sees 5 – 8 pct rise in full – year EPS

03 Feb 2015 - 08:30

(Corrects paragraph 1 to say UDG is based in Ireland, not UK)

Feb 3 (Reuters) – Ireland's UDG Healthcare Plc said it had made a strong start to the year and expected adjusted full-year earnings per share to be 5-8 percent ahead of last year on a constant currency basis.

The healthcare services provider added that if current exchange rates were sustained for the year, reported EPS would be higher than this range. ...

UDG, which reports results in euros, stands to benefit from the recent strengthening of the dollar and sterling against the euro.

The company reported adjusted earnings of 28.77 euro cents per share in the year ended Sept. 30, 2014. ...

(Reporting by Roshni Menon in Bengaluru; Editing by Gopakumar Warrier) ((roshni.menon@thomsonreuters.com; within UK +44 20 7542 1810, outside UK +91 80 6749 1136; Reuters Messaging: roshni.menon.thomsonreuters.com@reuters.net;)

Keywords: UDG HEALTH OUTLOOK/


By oldjoe1



Re: UDG Well Ahead Of Last Year........... by oldjoe1

  Tue, 03 Feb 2015 07:09:00 GMT

BRIEF – UDG Healthcare says Q1 trading well ahead of prior year

03 Feb 2015 - 07:19

Feb 3 (Reuters) – UDG Healthcare Plc

Has made a strong start to year with trading for quarter to 31 December 2014 well ahead of prior year
Expect constant currency adjusted diluted EPS (EPS) for year to 30 September 2015 to be between 5% and 8% ahead of last year
Source text for Eikon: ... Further company coverage: UDG.L

(Bengaluru Newsroom: +91 806 749 7920;)


By oldjoe1



UDG Well Ahead Of Last Year........... by oldjoe1

  Tue, 03 Feb 2015 06:53:00 GMT

UDG WELL AHEAD OF LAST YEAR...

Excelent Trading Update...

UDG HEALTHCARE PLC

FIRST QUARTER TRADING UPDATE

Strong Start to the Year and Full Year Guidance Issued


3 February 2015:
UDG Healthcare plc ("the Group"), a leading international provider of healthcare services issues the following trading update covering the period from 1 October to 31 December 2014. The company will hold its Annual General Meeting in Dublin at 12.00pm today.

Quarter to 31 December 2014

Group

<b>The Group has made a strong start to the year with trading for the quarter to 31 December 2014 well ahead of the prior year.</b>

LINK


By oldjoe1



UPDATE...Govt -epetition by dickie3times

  Sun, 15 Jun 2014 22:05:00 GMT

Thanks for all your support. We are over 4,027 votes!

(that's A LOT of irate investors!)

HMGovt epetition, make short selling illegal !

(or at least better regulated)

cast your vote here....
LINK

read more -( a lot more )
LINK


By dickie3times